BIO-key Reports Q3 2026 Results with Significant Growth in Software License Revenue
BIO-key (BKYI) reported third-quarter revenue of $1.48 million, a 4% decline year-over-year caused by the delay of a large international hardware order. However, the company saw a significant shift in its business model toward high-margin recurring software, with license fee revenue rising 39% to $1.3 million and gross margins expanding from 77% to 90%. The Middle East remains a primary growth driver, highlighted by a national biometric initiative with the Central Bank of Jordan and expansion into Saudi Arabia via a new subsidiary. Despite a net loss of $5.9 million per share—largely due to a one-time $4.5 million non-cash deemed dividend related to warrant inducement—the company successfully retired its remaining debt, leaving it effectively debt-free with improved working capital.
Topics: biometric initiative gross margin expansion middle east expansion net loss revenue growth